ALX ONCOLOGY HOLDINGS INC

ALXO11 Dec 2024
Healthcare
$1.66
-0.08 (-8.14%)
Lowest Today
$1.56
Highest Today
$1.72
Today’s Open
$1.66
Prev. Close
$1.72
52 Week High
$17.83
52 Week Low
$1.19
To Invest in ALX ONCOLOGY HOLDINGS INC

ALX ONCOLOGY HOLDINGS INC

Healthcare
ALXO11 Dec 2024
-0.08 (-8.14%)
1M
3M
6M
1Y
5Y
Low
$1.56
Day’s Range
High
$1.72
1.56
52 Week Low
$1.19
52-Week Range
52 Week High
$17.82
1.19
1 Day
-
1 Week
+1.28%
1 month return
+6.41%
3 month return
-27.58%
6 month return
-81.53%
1 Year return
-87.35%
3 Years return
-93.29%
5 Years return
-
10 Years return
-
Institutional Holdings
venBio Partners LLC
18.39
FMR Inc
11.12
TANG CAPITAL MANAGEMENT LLC
7.97
Vivo Capital, LLC
7.65
Redmile Group, LLC
7.27
BlackRock Inc
5.1
MPM Oncology Impact Management LP
4.57

Market Status

Fundamentals
Market Cap
90.72 mln
PB Ratio
0.62
PE Ratio
0
Enterprise Value
-53.3 mln
Total Assets
242.55 mln
Volume

Company Financials

Fund house & investment objective

Company Information
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Organisation
ALX ONCOLOGY HOLDINGS INC
Employees
89
Industry
Biotechnology
CEO
Mr. Jason W. Lettmann
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step